Engflag
Advertisements

Pizotifen

Quick links to important sections

Pizotifen

Pizotifen_DA
Advertisements
Advertisements

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Pizotifen

Quick Facts

Property Description
Active Ingredient Pizotifen (usually as Pizotifen malate)
Form Oral tablets, coated tablets, or liquid suspension
Pharmacological Class Serotonin Antagonist / Antimigraine Agent
Common Use Prophylaxis (prevention) of vascular headaches
Origin Synthetic organic compound

What is Pizotifen? Definition and Pharmacological Class

Pizotifen is a synthetic organic compound classified as a prescription-only medicine and structurally defined as a tricyclic benzocycloheptathiophene derivative. The substance, often administered as its salt form, Pizotifen malate, belongs to the pharmacological class of serotonin antagonists (specifically 5-HT2 receptors) and also acts as a potent antihistamine by blocking H1 receptors. This characteristic dual-action profile distinguishes it from many selective agents.

Pizotifen is clinically recognized for its role in modifying neurovascular activity and is typically indicated when other common prophylactic treatments are not suitable. The compound’s distinct chemical structure and mechanism have positioned it as a traditional and reliable agent in the management of recurrent headaches.

Composition, Origin, and Available Forms

As a single active ingredient product, Pizotifen contains the compound Pizotifen as the sole pharmacologically active component. Being a synthetic organic compound, its origin is chemical synthesis, rather than derivation from natural sources. Pizotifen is designed for oral administration and is reflected in its common dosage forms, which include various strengths of tablets and, in some regions, a liquid medicine or suspension. The availability of a liquid form provides a differentiating factor, allowing flexibility for patients who have difficulty swallowing solid medication.

What is the General Purpose of Pizotifen?

The general purpose of Pizotifen is the prophylactic management of recurrent vascular headaches, primarily including migraine headaches and certain cluster headaches. Pizotifen’s role is to help prevent the onset of these severe episodes, aiming to reduce their frequency and severity over time, rather than providing relief during an acute headache attack. It is used in a sustained manner to maintain stability in the neurological and vascular systems, serving as a foundational preventative measure against these disabling episodes.

Advertisements

What side effects are possible with Pizotifen?

Possible Side Effects

Like all medications, Pizotifen can cause side effects, although not everyone experiences them. The most common side effects are generally mild and may decrease over time:

  • Increased appetite and resulting weight gain
  • Drowsiness or somnolence
  • Fatigue or tiredness
  • Dizziness
  • Dry mouth
  • Nausea

Uncommon or Rare side effects include:

  • Gastrointestinal disturbances such as constipation
  • Headache
  • Nervousness, anxiety, insomnia
  • Mental/mood changes (e.g., confusion, depression, aggression)
  • Visual disturbances
  • Hypersensitivity reactions (e.g., rash, urticaria, swelling of the face/ankles)
  • Liver issues (e.g., elevated liver enzymes, hepatitis, jaundice)
  • Seizures (more common in patients with a history of epilepsy)

Important Safety Information and Precautions

Pizotifen should not be taken if you have a known hypersensitivity to the drug or its components, are taking Monoamine Oxidase Inhibitors (MAOIs), or have pyloroduodenal obstruction or stenosing pyloric ulcer.

Caution is advised in patients with:

  • Narrow-angle glaucoma (or a predisposition to it)
  • A predisposition to urinary retention (e.g., due to prostatic enlargement)
  • Kidney or liver impairment (dosage adjustment may be necessary)
  • Epilepsy

Due to the risk of drowsiness and dizziness, patients should avoid driving or operating heavy machinery until they know how the medication affects them. The sedative effects of Pizotifen may be increased by alcohol, sedatives, hypnotics, and other central nervous system depressants. Pizotifen is not for use in children under 2 years of age and is not recommended during breastfeeding.

Do not stop taking Pizotifen abruptly; the dosage should be reduced gradually under medical supervision to avoid potential withdrawal symptoms such as tremor, anxiety, and depression.

Advertisements

Overdose and Emergency Response

Pizotifen overdose is officially documented to present with specific Central Nervous System (CNS) effects, including drowsiness, sedation, dizziness, confusion, nausea, and vomiting. Regulatory labeling also notes anticholinergic manifestations such as pyrexia (fever) and dryness of the mouth. The documented severe or life-threatening outcomes include respiratory paralysis, coma, and severe hypotension (low blood pressure).

Official documents state that overdose in children carries a risk of cardiorespiratory collapse and may involve signs of CNS excitation, hallucinations, and convulsions (seizures).

Governmental guidance mandates that individuals seek immediate medical attention for a suspected overdose. It is an explicit requirement to contact a healthcare practitioner, hospital emergency department, or a regional Poison Control Centre immediately, even if the exposed person remains asymptomatic.

Overdose treatment is classified as symptomatic and supportive. Regulatory procedures recommend the administration of activated charcoal and the use of short-acting benzodiazepines to manage documented CNS excitation or convulsions. Continuous ECG monitoring is required, with specific attention to the QRS and QT intervals, alongside the necessary surveillance of the cardiovascular and respiratory systems.

Advertisements

Therapeutic Uses of Pizotifen

Pizotifen is commonly used for the sustained, preventative management of recurrent vascular headaches, which include migraine episodes and cluster headaches. The therapeutic domain is preventative management of recurrent symptoms, which differs from approaches used during acute symptomatic episodes. The medication is relevant for easing symptoms that interfere with daily comfort.

A primary goal is to help ease the overall symptom burden over time. This medication is used to help address symptom clusters that may become intense or disruptive, supporting a reduction in the frequency, intensity, and duration of episodes. The medication may be relevant in clinical settings for managing troublesome headache cycles that significantly interfere with daily functioning.

“Its role is generally considered supportive in easing the burden of recurrent manifestations and assisting with symptom management.”

Quick Fact: Relief for Recurrent Headaches

Use Classification Target Symptom Cluster Patient Benefit
Prophylactic Management Frequent, severe, disabling vascular headaches Contributes to easing the overall symptom load
Sustained Relief Context High frequency, high intensity, long duration Supports more steady coping with symptom fluctuations

Regulatory References

  1. NPS MedicineWise (Australian TGA)
Advertisements

Eligibility and Restrictions for Use

Pizotifen eligibility is defined by official regulatory documentation, outlining populations who are absolutely contraindicated and those for whom use is restricted.

Contraindicated Populations

Use is strictly prohibited in patients with known hypersensitivity to Pizotifen or any components in the formulation. It is also contraindicated for individuals concurrently taking Monoamine Oxidase Inhibitors (MAOIs). Age restrictions vary regionally, but Pizotifen is contraindicated or not recommended for children under 2 years in some regions and under 12 years in others.

Condition-Based Restrictions

Use requires caution and may necessitate dosage adjustment in patients with hepatic (liver) impairment or renal (kidney) impairment, as the drug is metabolized by the liver and eliminated through the kidneys. Caution is also advised in patients with a history of epilepsy, narrow-angle glaucoma, or conditions predisposing to urinary retention.

Reproductive Status Eligibility

Use during pregnancy is not established as safe in humans and is only permitted if the potential benefit outweighs the risk to the fetus. Use is not recommended for women who are breastfeeding.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Category Official Regulatory Findings
Medicinal product categories with documented interactions Central Nervous System (CNS) Depressants, Adrenergic Neurone Blockers, Drugs that exclusively undergo N-glucuronidation.
Specific interacting medicines (if explicitly listed) Monoamine Oxidase Inhibitors (MAOIs), Cisapride, Alcohol.
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic effects (CNS reinforcement, antagonism of hypotensive effect), Pharmacokinetic interaction via competition for the N-glucuronidation metabolic pathway.
Timing-based interaction rules (if applicable) N/A (No mandatory time separation rules are explicitly documented).
Population-specific interaction notes (if applicable) Hepatic Impairment and Renal Impairment due to the possibility of drug and/or metabolite accumulation.
Interaction-related restrictions Monoamine Oxidase Inhibitors (MAOIs) are classified as a combination that should be avoided.

Interaction Classifications (High-Level)

Classification Official Regulatory Findings
Interaction severity classification (as defined in official documents) Contraindicated/Avoided Combination (MAOIs); Use-with-Caution/Enhanced Effects (CNS Depressants, Alcohol); Efficacy-Reduction (Adrenergic Neurone Blockers).
Regulatory basis (EMA / FDA / etc.) Information derived from governmental product monographs and Summaries of Product Characteristics (SmPC).
Interaction-context constraints (as defined in official documents) Caution is required in patients with hepatic or renal impairment due to the potential for drug accumulation.

Official interaction statements

  • The co-administration of Monoamine Oxidase Inhibitors (MAOIs) is restricted, as these can prolong and intensify the anticholinergic effects of Pizotifen.
  • The central effects of alcohol and other CNS depressants (including sedatives, hypnotics, and psychotherapeutic agents) may be enhanced upon co-administration.
  • Pizotifen antagonizes the hypotensive effect of adrenergic neurone blockers, resulting in a reduction of their intended efficacy.
  • An increased plasma concentration of Pizotifen cannot be excluded when co-administered with drugs that exclusively undergo N-glucuronidation, indicating a pharmacokinetic risk.
  • Caution is officially required in patients with hepatic or renal impairment due to the potential for the accumulation of the parent drug and its metabolites.

Connection to the overall interaction profile

Regulatory documents define Pizotifen's interaction structure primarily through two categories: Pharmacodynamic Reinforcement, notably with CNS depressants and alcohol, and Absolute Restriction against co-administration with MAOIs. A documented Pharmacokinetic Competition mechanism concerning N-glucuronidation also contributes to the profile by establishing a risk of increased Pizotifen exposure with specific co-medications. Specific patient conditions like hepatic or renal impairment are designated as contexts requiring caution due to documented accumulation risk.

Advertisements

Mechanism of Action

How Pizotifen Works

Pizotifen functions as a polyvalent antagonist by blocking the effects of the biogenic amines serotonin (at 5-HT 2A and 5-HT 2C receptors) and histamine (at the H1 receptor). This dual antagonism prevents the amines from initiating receptor-mediated signaling on the neurovascular unit, resulting in the modulation of signaling within these systems. The antagonism of 5- HT2 and H1 receptors influences the responsiveness of the cranial blood vessels.

By blocking the signaling of serotonin and histamine, the drug limits their ability to increase the porosity (permeability) of small blood vessels and induce passive distension of extracranial arteries. The modulation of vascular integrity and the reduction of abnormal vessel permeability restrict the transudation of fluid and pro-inflammatory mediators (like plasmakinin) into the surrounding tissue. The restriction of perivascular irritants influences the threshold of nociceptive signaling. Pizotifen also influences vascular function by inhibiting the reuptake of serotonin by blood platelets, which results in the modulation of plasma serotonin levels. Furthermore, its engagement with secondary receptors, including alpha-adrenergic and tryptamine receptors, broadens its physiological influence, though the mechanism’s biological response may lessen over time due to tolerance.

Advertisements

Dosage and Administration Information

The administration of pizotifen is designated by the oral route, utilizing either film-coated tablets in 0.5 mg and 1.5 mg strengths or, in some regions, a syrup formulation. Use typically begins with an initial adult dosage of 0.5 mg daily, which is then progressively increased (titrated) to establish the average maintenance dosage of 1.5 mg daily. The dosage is adjusted to meet individual patient requirements, but must not exceed the 4.5 mg maximum daily dose. Up to 3 mg may be given as a single administration.

Frequency and Timing Principles

The total daily amount may be taken either as a single dose at night or administered in two or three divided doses throughout the day. The medicine can be taken with or without food. For the tablet form, the medication is intended to be swallowed whole with a drink. If a dose is missed, the procedural instruction is to avoid taking a double dose to compensate.

Use Patterns and Population-Specific Rules

Pizotifen requires an adequate treatment duration, with standard practice suggesting a trial of at least 2 to 3 months to determine the prophylactic effect. Discontinuation of therapy must involve gradual withdrawal (tapering) over a period, such as two weeks. For pediatric patients starting at two years of age, the maximum daily dose is limited to 1.5 mg, typically given in divided doses. Caution is required, and dosage adjustment may be necessary in patients with renal or hepatic impairment. The labeled instructions generally do not indicate a requirement for different dosages in older adults.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pizotifen

Evidence for Use in Recurrent Migraine Prophylaxis

Pizotifen was evaluated in studies exploring its role in the prevention, or prophylaxis, of recurrent vascular headaches. The foundation of the research base consists mainly of Randomized Controlled Trials (RCTs), which are comparative studies designed to assess episodic symptom patterns over defined time intervals. These studies primarily included adults experiencing cycles of stability and flare-ups related to migraine, which are conditions characterized by fluctuating or episodic manifestations.

In the trials, researchers monitored several key outcomes related to physical discomfort. These included the evaluation of migraine attack frequency (the number of attacks per month), and attack characteristics such as severity and duration. Studies reported how symptoms were measured in the observed populations over the study period. Findings describe patterns observed in the studies related to the measurement of attack frequency.

The Study Landscape and Outcomes Measured

This part will detail the specific parameters and measures utilized by researchers in the primary studies, outlining how the evidence base evaluated outcomes related to headache characteristics, such as intensity, duration, and the proportion of participants who were observed in studies to have a certain level of attack frequency.

Long-Term Data and Extended Follow-up Periods

Most of the initial randomized trials for Pizotifen were research exploring short-term symptom changes, typically running for observation periods of 12 to 16 weeks (around three to four months). However, there is limited information for long-term outcomes and the durability of any observed response. Long-term outcomes are not fully established, and follow-up durations were limited in many of the core studies.

Evidence Gaps and Areas of Uncertainty

The research highlights what is known — and what is still uncertain — about Pizotifen. A key area of uncertainty is the low certainty classification assigned to the evidence base by some systematic reviews. This is largely due to the fact that the original trials are decades old, and sample sizes were modest in many of the studies used for comparison.

There is a recognized need for modern, methodologically robust clinical trials to better characterize the role of Pizotifen in the current evidence landscape. The findings describe group patterns, not personal outcomes, and uncertainty remains regarding consistent results when comparing Pizotifen to other active comparator treatments.

Key Studies & References

  1. Headaches in over 12s: diagnosis and management - Recommendations for research (NICE Guideline CG150)
  2. Details for: SANDOMIGRAN DS - Drug and Health Product Register (Health Canada Product Monograph)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Pizotifen (FAQ)

Q: Is Pizotifen available over the counter, or is it prescription only?

A: According to official regulatory classifications, Pizotifen is a prescription-only medicine. It must be prescribed by a licensed healthcare professional.

Q: Is Pizotifen used for tension headaches as well as migraines?

A: Official product information states that Pizotifen is indicated for the prevention of recurrent vascular headaches, including typical or atypical migraine and cluster headache. However, regulatory documents also indicate that it is generally considered less effective for treating tension headache.

Q: What are the signs that Pizotifen might not be working for me?

A: Studies and regulatory guidance suggest that a trial of at least 2 to 3 months is typically needed to determine the drug's full preventative effect. If no reduction in the frequency or severity of vascular headaches is noted after this time, it may be appropriate to consult with a healthcare professional to re-evaluate the treatment.

Q: How long can a person safely stay on Pizotifen medication?

A: Most of the initial clinical trials for Pizotifen were short-term, typically lasting about 12 to 16 weeks. Official documents note that there is limited information available regarding long-term outcomes and the durability of the response over extended periods of use.

Q: Does Pizotifen affect blood pressure or heart rate?

A: Changes to blood pressure or heart rate are not listed as common side effects in the official product information. However, serious symptoms like an increased heart rate (tachycardia) or low blood pressure (hypotension) have been reported as signs of an overdose.

Q: Is Pizotifen sometimes prescribed for appetite stimulation?

A: While increased appetite and resulting weight gain are listed as very common side effects in regulatory documents, the approved therapeutic purpose for Pizotifen is limited to the prophylaxis of vascular headaches. The official label does not state an indication for use as an appetite stimulant.

Q: Is Pizotifen considered a preventive treatment or an abortive one for headaches?

A: Pizotifen is exclusively intended for the prophylactic (preventive) treatment of recurrent vascular headaches. It is not effective and should not be used for relieving a migraine attack once it has already started.

Q: Is it normal to feel a bit dizzy when first starting Pizotifen?

A: Dizziness is listed as a common side effect of Pizotifen. Since the sedative effects may be highest when starting the medication, caution is necessary when the drug is initiated, particularly regarding activities that require full alertness.

Q: Does Pizotifen have a potential for dependence or addiction?

A: The official product label does not use the terms dependence or addiction. However, it mandates a gradual withdrawal (tapering) of the dose to avoid potential withdrawal symptoms such as tremor, anxiety, and depression if the medication is stopped abruptly.

Q: Can Pizotifen make existing conditions like glaucoma worse?

A: Due to the drug's slight anticholinergic effect, caution is officially required in patients with narrow-angle glaucoma or a predisposition to it. Individuals with this condition require clinical assessment before use.

Q: What is the potential impact of Pizotifen on liver or kidney function?

A: Caution and dosage adjustment may be necessary for patients with existing hepatic (liver) or renal (kidney) impairment due to the potential for the drug to accumulate in the body. In rare cases, liver injury, including elevated liver enzymes and hepatitis, has been reported.

Q: Is Pizotifen suitable for people with a history of epilepsy or seizures?

A: Official regulatory warnings state that the drug should be used with caution in patients with a history of epilepsy. Seizures have been observed more frequently in this patient group.

Q: Is Pizotifen safe for elderly patients, and are there special considerations?

A: The labeled instructions generally do not indicate a requirement for different dosages in older adults. However, clinical assessment is required for use in any patient population, especially those with multiple health conditions.

Q: Does Pizotifen lose its effectiveness over time?

A: The official mechanism of action notes that the drug’s biological response may lessen over time due to the body potentially developing tolerance to the medication's effects.

Q: Is it true that Pizotifen can help improve sleep quality?

A: Since a common side effect is drowsiness, the nightly dosing recommendation is intended to manage this sedative effect. The drug is not officially approved or indicated for improving sleep quality.

Q: Are there any specific blood tests required while taking Pizotifen?

A: While routine blood tests are not explicitly required in the official label, rare cases of elevated liver enzymes and liver injury have been reported. The decision for monitoring or specific blood testing is made by a healthcare professional based on individual patient circumstances and risk factors.

Q: Is Pizotifen commonly used for cluster headaches?

A: The drug's official indications include the prophylactic treatment of recurrent vascular headaches, which explicitly includes cluster headache (Horton's syndrome) in addition to migraine.

Q: What happens if I accidentally take two doses of Pizotifen close together?

A: Signs of taking too much (overdose) include severe drowsiness, dry mouth, dizziness, nausea, and confusion. If an overdose is suspected, it is necessary to contact emergency services or a poison control center immediately.

Q: Does Pizotifen interact with any medications for depression or anxiety?

A: Pizotifen is contraindicated (must be avoided) when taken with Monoamine Oxidase Inhibitors (MAOIs), a class of antidepressants. Furthermore, the central effects of other CNS depressants (including sedatives, hypnotics, and psychotherapeutic agents) may be enhanced.

Q: Can Pizotifen cause dry mouth or dry eyes?

A: Dry mouth is listed as a common side effect of Pizotifen. Dry eyes are not specifically listed, but the drug's anticholinergic properties require caution in patients with narrow-angle glaucoma.

Q: What kind of evidence is there about Pizotifen's long-term safety?

A: The official evidence base for Pizotifen, consisting mostly of older randomized trials, has limited information available for long-term safety and outcomes. Most studies were designed for short-term observation, typically 3 to 4 months.

Q: Why do some people use Pizotifen specifically to gain weight?

A: Increased appetite and weight gain are well-documented and very common side effects of the medication. This observation may influence its use, even though the drug is not officially approved or indicated for the purpose of weight gain.

Q: Is Pizotifen a type of antidepressant or anxiety medication?

A: Pizotifen is classified as a serotonin and histamine antagonist. It is officially indicated for the prophylaxis of vascular headaches and is not approved for use as an antidepressant or anxiety medication.

Q: Are there any common foods or drinks I should avoid while taking Pizotifen?

A: Official information states that the medicine can generally be taken with or without food. However, co-administration with alcohol is restricted because it can significantly enhance the sedative and central effects of the drug.

Q: What other medications commonly interact with Pizotifen?

A: Documented interactions include those with Monoamine Oxidase Inhibitors (MAOIs), alcohol, CNS depressants (such as sedatives, hypnotics, and other psychotherapeutic agents), and adrenergic neurone blockers.

Advertisements

How should Pizotifen be stored and disposed of?

Storage and Disposal of Pizotifen

Pizotifen tablets must be stored according to official regulatory requirements to maintain product stability and quality. The medicine should be stored at room temperature, specifically below 30 C (86 F), and must be protected from both light and moisture. Do not refrigerate or freeze the medication. To ensure stability, keep the tablets in the original container or packaging until use.

All Pizotifen must be stored out of the sight and reach of children.

Disposal Instructions

To dispose of unused or expired Pizotifen, do not throw it away with household trash or flush it down a toilet or sink. The official instruction is to return the unused product to a pharmacist or an approved local collection scheme for destruction as pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Pizotifen found in:

A-Z Index: